Walgreens has signed a deal with Boehringer Ingelheim to use its community pharmacies as clinical trial sites for people living with obesity and type 2 diabetes.
The drugmaker is moving into Phase III studies for survodutide, which it is developing in partnership with Zealand Pharma. It is expected to compete with other popular GLP-1 drugs currently on the market, such as Ozempic and Wegovy from Novo Nordisk. The drug has passed trials for safety and effectiveness, and the latest trials compare its efficacy with existing treatments. After the Phase III trial is completed, the company can request FDA review.
Walgreens' objective is to leverage its national presence, community relationships and data-driven clinical trials solutions to help identify and reach potential study participants for clinical trials.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
